Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Lexicon Pharmaceuticals, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
Lexicon Pharmaceuticals, Inc. has 4 disclosed suppliers and 13 disclosed customers. Each one is named in an SEC filing, either Lexicon Pharmaceuticals, Inc.’s own annual report or the counterparty’s, and carries the sentence that discloses it.
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“Lexicon and one of its subsidiaries entered into a loan and security agreement (the "Loan Agreement") with Oxford Finance LLC and the lenders listed therein ("Oxford") in March 2022 (as subsequently amended) that originally provided up to $ 150 million in borrowing capacity (the "Oxford Term Loan s").”
FILING10-K0001062822-26-000050cik 0001062822
“We are responsible for providing clinical supply of LX9851 to Novo Nordisk at an agreed upon transfer price for a specified time period, following which Novo Nordisk will be responsible for all manufacturing and supply activities for LX9851.”
FILING10-K0001062822-26-000050cik 0001062822
“We and Viatris have entered into a manufacturing and supply agreement pursuant to which we supply Viatris' development and commercial requirements of sotagliflozin and Viatris pays an agreed upon transfer price for such supply.”
FILING10-K0001062822-26-000050cik 0001062822
“10.25 — Preferred Stock Purchase Agreement , dated January 29, 2026, with Artal Participations S.à r.l. (filed as Exhibit 10.2 to the Company's Current Report on Form 8-K dated January 29, 2026 and incorporated by reference herein).”
FILING10-K0001062822-26-000050cik 0001062822
“10.24 — Purchase Agreement , dated as of January 29, 2026, with Artal Participations S.à r.l., Invus Public Equities Advisors, LLC, Invus Global Management, LLC, Invus US Partners LLC, Invus Advisors, L.L.C., Invus Public Equities, L.P., Invus, Siren, LLC, Ulys, L.L.C and Mr. Raymond Debbane (filed as Exhibit 10.1 to the Company's Current Report on Form 8-K dated January 29, 2026 and incorporated by reference herein).”
FILING10-K0001062822-26-000050cik 0001062822
“10.24 — Purchase Agreement , dated as of January 29, 2026, with Artal Participations S.à r.l., Invus Public Equities Advisors, LLC, Invus Global Management, LLC, Invus US Partners LLC, Invus Advisors, L.L.C., Invus Public Equities, L.P., Invus, Siren, LLC, Ulys, L.L.C and Mr. Raymond Debbane (filed as Exhibit 10.1 to the Company's Current Report on Form 8-K dated January 29, 2026 and incorporated by reference herein).”
FILING10-K0001062822-26-000050cik 0001062822
“10.24 — Purchase Agreement , dated as of January 29, 2026, with Artal Participations S.à r.l., Invus Public Equities Advisors, LLC, Invus Global Management, LLC, Invus US Partners LLC, Invus Advisors, L.L.C., Invus Public Equities, L.P., Invus, Siren, LLC, Ulys, L.L.C and Mr. Raymond Debbane (filed as Exhibit 10.1 to the Company's Current Report on Form 8-K dated January 29, 2026 and incorporated by reference herein).”
FILING10-K0001062822-26-000050cik 0001062822
“10.24 — Purchase Agreement , dated as of January 29, 2026, with Artal Participations S.à r.l., Invus Public Equities Advisors, LLC, Invus Global Management, LLC, Invus US Partners LLC, Invus Advisors, L.L.C., Invus Public Equities, L.P., Invus, Siren, LLC, Ulys, L.L.C and Mr. Raymond Debbane (filed as Exhibit 10.1 to the Company's Current Report on Form 8-K dated January 29, 2026 and incorporated by reference herein).”
FILING10-K0001062822-26-000050cik 0001062822
“10.24 — Purchase Agreement , dated as of January 29, 2026, with Artal Participations S.à r.l., Invus Public Equities Advisors, LLC, Invus Global Management, LLC, Invus US Partners LLC, Invus Advisors, L.L.C., Invus Public Equities, L.P., Invus, Siren, LLC, Ulys, L.L.C and Mr. Raymond Debbane (filed as Exhibit 10.1 to the Company's Current Report on Form 8-K dated January 29, 2026 and incorporated by reference herein).”
FILING10-K0001062822-26-000050cik 0001062822
“4.1 — Securities Purchase Agreement , dated June 17, 2007, with Invus, L.P. (filed as Exhibit 10.1 to the Company's Current Report on Form 8-K dated June 17, 2007 and incorporated by reference herein).”
FILING10-K0001062822-26-000050cik 0001062822
“10.24 — Purchase Agreement , dated as of January 29, 2026, with Artal Participations S.à r.l., Invus Public Equities Advisors, LLC, Invus Global Management, LLC, Invus US Partners LLC, Invus Advisors, L.L.C., Invus Public Equities, L.P., Invus, Siren, LLC, Ulys, L.L.C and Mr. Raymond Debbane (filed as Exhibit 10.1 to the Company's Current Report on Form 8-K dated January 29, 2026 and incorporated by reference herein).”
FILING10-K0001062822-26-000050cik 0001062822
“10.24 — Purchase Agreement , dated as of January 29, 2026, with Artal Participations S.à r.l., Invus Public Equities Advisors, LLC, Invus Global Management, LLC, Invus US Partners LLC, Invus Advisors, L.L.C., Invus Public Equities, L.P., Invus, Siren, LLC, Ulys, L.L.C and Mr. Raymond Debbane (filed as Exhibit 10.1 to the Company's Current Report on Form 8-K dated January 29, 2026 and incorporated by reference herein).”
FILING10-K0001062822-26-000050cik 0001062822
“10.24 — Purchase Agreement , dated as of January 29, 2026, with Artal Participations S.à r.l., Invus Public Equities Advisors, LLC, Invus Global Management, LLC, Invus US Partners LLC, Invus Advisors, L.L.C., Invus Public Equities, L.P., Invus, Siren, LLC, Ulys, L.L.C and Mr. Raymond Debbane (filed as Exhibit 10.1 to the Company's Current Report on Form 8-K dated January 29, 2026 and incorporated by reference herein).”
FILING10-K0001062822-26-000050cik 0001062822
“We have agreed to pay Bristol-Myers Squibb up to $34.5 million in clinical and regulatory milestones for the first indication and up to $16 million in clinical and regulatory milestones for each of the second and third indications, if applicable.”
FILING10-K0001062822-26-000050cik 0001062822
“1.1 — Open Market Sale Agreement℠ , dated December 29, 2023, with Jefferies LLC (filed as Exhibit 1.1 to the Company's Current Report on Form 8-K dated December 29, 2023 and incorporated by reference herein).”
FILING10-K0001062822-26-000050cik 0001062822
“10.15 — Office Lease dated July 30, 2024, with RFL NO.4 Limited Partnership (filed as Exhibit 10.3 to the Company's Quarterly Report on Form 10-Q for the period ended June 30, 2024 and incorporated by reference herein).”
FILING10-K0001062822-26-000050cik 0001062822
“In addition, we are entitled to receive clinical and regulatory milestone payments ranging, depending on the timing and extent of our efforts in the alliance, up to $76 million for each drug developed by Bristol-Myers Squibb under the alliance.”
FILING10-K0001062822-26-000050cik 0001062822
Watchlist prices, news filtered to it, and its next report on your desk.
No intraday reading yet this session.
LXRX (Lexicon Pharmaceuticals, Inc.) has 4 disclosed suppliers and 13 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.